Reported Earlier, 60 Degrees Pharma Announces IRB Approval Of Clinical Study Of Tafenoquine For Treatment Of Babesiosis In Immunocompromised Patients With Persistent Babesia microti Despite Prior Treatment

Author: Benzinga Newsdesk | July 09, 2024 08:02am

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))))) ("60 Degrees Pharmaceuticals" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced ethics approval of an open label, expanded access study of the ARAKODA® regimen of tafenoquine in combination with standard of care regimens in immunosuppressed patients with persistent/relapsing babesiosis.

The goal of the study is to confirm the findings of an 80 percent babesiosis cure rate in humans observed in a similar population in an earlier case series of tafenoquine completed by Yale School of Public Health (YSPH) in April 2024 and published in the journal, Clinical Infectious Diseases. The YSPH case series showed a cure rate (with a 95 percent confidence interval) of 80 percent (30-100 percent) in a series of five immunosuppressed patients who were administered weekly tafenoquine following a loading dose in combination with standard of care medications.

Posted In: SXTP